top of page

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Apr 17, 2025
1 min read

He describes the market potential of the company's HIF-2⍺, a target that has already been de-risked by a large pharma, why he believes being Fc silent will allow Arcus to succeed in TIGIT where others have failed, and a CD73 program that is enrolling very quickly in pancreatic cancer.

https://vimeo.com/1076324917?share=copy

Recent Posts

From NYSE: Noetik has been building a large database from patient tumor samples to use AI to help understand which patients are more likely to respond to medicines in the future

From NYSE: Noetik has been building a large database from patient tumor samples to use AI to help understand which patients are more likely to respond to medicines in the future

From NYSE: Alloy Therapeutics, which has a service provider model of helping other companies develop therapies, recently crossed the $1B valuation mark on their series E and is now fully integrated

From NYSE: Alloy Therapeutics, which has a service provider model of helping other companies develop therapies, recently crossed the $1B valuation mark on their series E and is now fully integrated

From NYSE: Anthropic called out Manifold Bio as a key feedback provider when they announced Claude for life sciences recently. CEO Gleb Kuznetsov explains, and updates us on the brain shuttle program

From NYSE: Anthropic called out Manifold Bio as a key feedback provider when they announced Claude for life sciences recently. CEO Gleb Kuznetsov explains, and updates us on the brain shuttle program

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page